We are currently living in the “genomic era.” In the last decade, high-throughput genomic analyses have generated massive quantities of data that can be used to explore gene function in specific biological settings. In the field of cancer research, studies performed in a variety of laboratories and by a number of large-scale projects, like The Cancer Genome Atlas (TCGA, http://cancergenome. nih. gov/, accessed October 31, 2016) and the International Cancer Genome Consortium (ICGC), 1 have given researchers an unparalleled amount of information on many different tumors through several platforms such as: mRNA expression arrays, comparative genomic hybridization arrays, DNA methylation arrays, exome sequencing, RNA sequencing, reverse protein phase arrays, and clinical parameters. 2 Consolidating these data